Clinical characteristics and thromboembolic risk of atrial fibrillation patients with and without congestive heart failure. Results from the CRATF study
- PMID: 30407304
- PMCID: PMC6250503
- DOI: 10.1097/MD.0000000000013074
Clinical characteristics and thromboembolic risk of atrial fibrillation patients with and without congestive heart failure. Results from the CRATF study
Erratum in
-
Clinical characteristics and thromboembolic risk of atrial fibrillation patients with and without congestive heart failure. Results from the CRATF study: Erratum.Medicine (Baltimore). 2019 Nov;98(45):e18071. doi: 10.1097/MD.0000000000018071. Medicine (Baltimore). 2019. PMID: 31702687 Free PMC article. No abstract available.
Abstract
Congestive heart failure (CHF) and atrial fibrillation (AF) frequently coexist and are associated with increased risk of cardiovascular events.To compare baseline characteristics, comorbidities and pharmacotherapy in AF patients with concomitant CHF to those without CHF.The study included 3506 real-life AF patients with (37.1%) and without CHF - participants of the multicentre, retrospective MultiCenter expeRience in AFib patients Treated with OAC (CRAFT) trial (NCT02987062).All patients were treated with non-vitamin K antagonist oral anticoagulants (NOAC) or vitamin K antagonists (VKA). The frequency of NOAC among patients with and without CHF was 45.6% and 43.2%, respectively (P = .17). Patients with CHF were older (73.3 vs 64.7 years, P <.001), less likely to be women (37.4% vs 42%, P = .007), had higher CHA2DS2-VASc score (3.8 ± 1.7 vs 2.6 ± 1.8, P <.001), more often had permanent AF (53.0% vs 13.4%, P <.001), chronic obstructive pulmonary disease (16.7% vs 4.9%, P <.001), coronary artery disease (64.3% vs 29.8%, P <.001), peripheral vascular disease (65.3% vs 31.4%, P <.001), chronic kidney disease (43.1% vs 10.0%, P <.001), liver fibrosis (5.7% vs 2.6%, P <.001), neoplasm (9.6% vs 7.3%, P = .05), history of composite of stroke, transient ischemic attack or systemic embolization (16.2% vs 10.7%, P <.001), pacemaker (27.4% vs 22.1%, P = .004), implantable cardioverter-defibrillator (22.7% vs 0.8%, P <.001) or transaortic valve implantation (4.0% vs 0.8%, P <.001), cardiac resynchronization therapy (8.7% vs 0.3%, P <.001), composite of kidney transplantation, hemodialysis or creatinine level > 2.26 mg/dL (3.6% vs 0.8%, P <.001) and had less often hypertension (69.4% vs 72.5%, P = .05).Patients with AF and CHF had a higher thromboembolic risk and had more concomitant diseases.
Conflict of interest statement
The authors have no conflicts of interest to disclose.
Similar articles
-
Assessment of the CHA2DS2-VASc Score in Predicting Ischemic Stroke, Thromboembolism, and Death in Patients With Heart Failure With and Without Atrial Fibrillation.JAMA. 2015 Sep 8;314(10):1030-8. doi: 10.1001/jama.2015.10725. JAMA. 2015. PMID: 26318604
-
The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.J Am Coll Cardiol. 2013 Dec 10;62(23):2199-204. doi: 10.1016/j.jacc.2013.08.1623. Epub 2013 Sep 18. J Am Coll Cardiol. 2013. PMID: 24055744
-
Comparison of clinical characteristics of real-life atrial fibrillation patients treated with vitamin K antagonists, dabigatran, and rivaroxaban: results from the CRAFT study.Kardiol Pol. 2018;76(5):889-898. doi: 10.5603/KP.a2018.0027. Epub 2018 Jan 19. Kardiol Pol. 2018. PMID: 29350386 Clinical Trial.
-
Should Every Patient With Atrial Fibrillation and a CHA2DS2-VASc Score of 1 Be Anticoagulated? A Systematic Review of 37,030 Patients.Cardiol Rev. 2019 Sep/Oct;27(5):249-255. doi: 10.1097/CRD.0000000000000246. Cardiol Rev. 2019. PMID: 31393287
-
Non-vitamin K antagonist oral anticoagulants in atrial fibrillation accompanying mitral stenosis: the concept for a trial.Europace. 2016 Jan;18(1):6-11. doi: 10.1093/europace/euv288. Epub 2015 Oct 7. Europace. 2016. PMID: 26450845 Review.
Cited by
-
Clinical characteristics and thromboembolic risk of atrial fibrillation patients with and without congestive heart failure. Results from the CRATF study: Erratum.Medicine (Baltimore). 2019 Nov;98(45):e18071. doi: 10.1097/MD.0000000000018071. Medicine (Baltimore). 2019. PMID: 31702687 Free PMC article. No abstract available.
-
Thromboembolism in Patients with Hypertrophic Cardiomyopathy.Int J Med Sci. 2021 Jan 1;18(3):727-735. doi: 10.7150/ijms.50167. eCollection 2021. Int J Med Sci. 2021. PMID: 33437207 Free PMC article. Review.
References
-
- Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA 2001;285:2370–5. - PubMed
-
- Lip GY, Laroche C, Popescu MI, et al. Heart failure in patients with atrial fibrillation in Europe: a report from the EURObservational research programme pilot survey on atrial fibrillation. Eur J Heart Fail 2015;17:570–82. - PubMed
-
- Ponikowski P, Anker SD, AlHabib KF, et al. Heart failure: preventing disease and death worldwide. ESC Heart Failure 2014;1:4–25. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical